Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis
The overall MIDD approach supported the nemolizumab program by confirming the recommended dosing regimen of 30 mg every four weeks with a 60 mg loading dose in all patients with AD.
Authors
- Floris Fauchet
- Wannee Kantasiripitak (ORCID: https://orcid.org/0000-0001-9285-799X)
- Nathalie Wagner
- Khaled Benkali
- Emilie Schindler (ORCID: https://orcid.org/0000-0002-4654-1131)
- Luca Loprete (ORCID: https://orcid.org/0000-0001-7616-6232)
- Petra M. Jauslin
- Eline van Maanen
- Liliana Ulianov (ORCID: https://orcid.org/0009-0001-2897-6895)
- Anna Largajolli (ORCID: https://orcid.org/0000-0001-8034-5567)
- Vincent Duval (ORCID: https://orcid.org/0009-0008-0138-7258)
- Antonio Gonçalves
- Tomohisa Saito
- Michael Graeber
- Jonathan I. Silverberg
- Andreas Wollenberg
- Christophe Piketty
Institutions
- Roche (Switzerland) (CH)
- George Washington University (US)
- Galderma (United States) (US)
- Chugai Pharma (United States) (US)
- Certara (United States) (US)
- Universitair Ziekenhuis Brussel (BE)
- Galderma (Switzerland) (CH)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1002/bcp.70435
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00